OTCMKTS:ENDV Endonovo Therapeutics (ENDV) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 10/14/2026 10:21 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Endonovo Therapeutics Stock (OTCMKTS:ENDV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Endonovo Therapeutics alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0002Volume206,270 shsAverage Volume5 shsMarket Capitalization$144.57 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Endonovo Therapeutics, Inc. is a biotechnology company focused on regenerative medicine and bioelectronic therapies. The company has worked on technologies intended to use electrical stimulation to influence cellular activity and support the repair or regeneration of damaged tissues. Its research and development activities have included noninvasive therapeutic platforms designed for potential applications in areas such as wound healing, cardiovascular care and other conditions involving tissue injury. Publicly available information about the company’s specific products, commercial operations and geographic reach is limited. Endonovo Therapeutics trades under the symbol ENDV on the OTC Markets. Detailed, current information about its leadership team and the status of its development programs was not reliably available.AI Generated. May Contain Errors. Read More Receive ENDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENDV Stock News HeadlinesEndonovo Therapeutics Stock Price HistoryJune 3, 2026 | investing.comEndonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 MillionDecember 4, 2023 | finance.yahoo.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Endonovo Therapeutics, Inc. (ENDV)November 21, 2023 | finance.yahoo.comLexeo Therapeutics Inc (LXEO)November 15, 2023 | investing.comEndonovo receives Taiwanese approval for SofPulse technologyOctober 13, 2023 | msn.comEndonovo's SofPulse® Secures Taiwan FDA ApprovalOctober 12, 2023 | finance.yahoo.comEndonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA DistributionAugust 22, 2023 | finance.yahoo.comSee More Headlines ENDV Stock Analysis - Frequently Asked Questions How have ENDV shares performed this year? Endonovo Therapeutics' stock was trading at $0.0001 at the beginning of 2026. Since then, ENDV stock has increased by 0.0% and is now trading at $0.0001. How do I buy shares of Endonovo Therapeutics? Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Endonovo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Endonovo Therapeutics investors own include ChronoScale Corporation Common Stock (CHRN), Energous (WATT), GE Aerospace (GE), The Goldman Sachs Group (GS), Chesapeake Energy (CHKAQ), Geron (GERN) and Micron Technology (MU). Company Calendar Today10/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ENDV CIK1528172 Webwww.endonovo.com Phone(800) 489-4774Fax818-230-9899Employees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$10 thousand Price / Sales14.46 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,445,710,000Free Float1,364,609,000Market Cap$144.57 thousand OptionableNot Optionable Beta-1.02 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:ENDV) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endonovo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endonovo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
